MARKET

CSII

CSII

Cardiovascular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.09
-0.65
-4.13%
After Hours: 15.09 0 0.00% 16:06 05/18 EDT
OPEN
15.39
PREV CLOSE
15.74
HIGH
15.73
LOW
14.95
VOLUME
292.54K
TURNOVER
408.43K
52 WEEK HIGH
44.57
52 WEEK LOW
14.12
MARKET CAP
615.45M
P/E (TTM)
-18.1632
1D
5D
1M
3M
1Y
5Y
Why Needham Is Concerned About Competition Despite Promising Pipeline For This MedTech Stock
Needham believes the most meaningful announcements for Cardiovascular Systems Inc (NASDAQ: CSII) over the last 18 months could be: Partnership with Innova Vascular to develop a portfolio of thrombectomy devices. 
Benzinga · 25m ago
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
Zacks · 05/05 13:44
--SVB Leerink Adjusts Cardiovascular Systems' Price Target to $20 from $25, Keeps Outperform Rating
MT Newswires · 05/05 13:31
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday.
Benzinga · 05/04 17:45
BRIEF-Cardiovascular Systems Reports 2022 Third Quarter Financial Results
reuters.com · 05/04 12:57
Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:25
Recap: Cardiovascular Systems Q3 Earnings
  Cardiovascular Systems (NASDAQ:CSII) reported its Q3 earnings results on Wednesday, May 4, 2022 at 06:05 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:21
Cardiovascular Systems GAAP EPS of -$0.25 beats by $0.03, revenue of $56.22M misses by $1.16M
Cardiovascular Systems press release (NASDAQ:CSII): FQ3 GAAP EPS of -$0.25 beats by $0.03. Revenue of $56.22M (-11.1% Y/Y) misses by $1.16M. As of March 31, 2022, CSI had cash and
Seekingalpha · 05/04 11:10
More
No Data
Learn about the latest financial forecast of CSII. Analyze the recent business situations of Cardiovascular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
0.00%Buy
57.14%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average CSII stock price target is 22.50 with a high estimate of 30.00 and a low estimate of 18.00.
High30.00
Average22.50
Low18.00
Current 15.09
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 269
Institutional Holdings: 40.20M
% Owned: 98.55%
Shares Outstanding: 40.79M
TypeInstitutionsShares
Increased
64
5.08M
New
30
755.42K
Decreased
49
3.48M
Sold Out
35
2.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.72%
Healthcare Equipment & Supplies
-2.41%
Key Executives
Chairman/President/Chief Executive Officer/Director
Scott Ward
Chief Financial Officer
Jeffrey Points
Chief Operating Officer
Rhonda Robb
Chief Human Resource Officer
Stephen Rempe
Executive Vice President
John Hastings
Chief Compliance Officer
Sandra Sedo
Vice President
David Whitescarver
General Counsel/Secretary
Alexander Rosenstein
Independent Director
Martha Aronson
Independent Director
William Cohn
Independent Director
Sachin Jain
Independent Director
Augustine Lawlor
Independent Director
Erik Paulsen
Independent Director
Stephen Stenbeck
Independent Director
Kelvin Womack
No Data
No Data
About CSII
Cardiovascular Systems, Inc. is a medical technology company, which is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed patented orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

Webull offers kinds of Cardiovascular Systems Inc stock information, including NASDAQ:CSII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSII stock methods without spending real money on the virtual paper trading platform.